Samara Capital Partners Fund II to acquire a significant stake in Sahajanand Medical Technologies Private Limited
Mumbai - Mid-market private equity firm Samara Capital Partners Fund II (“Samara”) has signed definitive agreements to invest up to USD 25MM in Sahajanand Medical Technologies Private Limited (“SMT”) for a significant stake.
Established in the year 1998, SMT is India's largest stent manufacturing company and sells its product in more than 60 countries across the world. It became the first indigenous player in India to successfully launch coronary stents and is also the first company in the world to get CE approval for drug eluting stents with biodegradable polymers.
SMT plans to establish the company as a significant global player with a complete suite of product offerings in the cardiovascular field along with Samara. As a part of the deal, Gautam Gode and Abhishek Kabra of Samara Capital will come on the board of SMT.
Gautam Gode, Co-Founder and MD at Samara Capital said: “Samara has been actively researching and investing in the healthcare space and this is our second investment in the medical devices and consumables sector, after the buyout of a surgical consumables platform in Lotus Surgicals. We believe that the SMT team has the credibility and experience to build a large and global quality business while providing world class products at affordable prices.”
Bhargav Kotadia, Vice Chairman of SMT said: “Our core values have been providing best quality medical products and making it affordable and accessible to all. SMT today is India’s largest manufacturer of cardiovascular medical stents and has become the first Indian medical devices manufacturing company to commence the Talent Randomised Clinical Trial (RCT) in Europe which will re-enforce the quality of its product offerings and irrefutably establish the company at a global level. We are very excited to partner with Samara and use their expertise and network to take SMT to newer heights”.
About Sahajanand Medical Technologies
Established in the year 1998, SMT became the first indigenous player in India to successfully launch coronary stent. SMT is also the first company to get CE approval for DES with Biodegradable Polymers in the world. It is India's largest stent manufacturing company and sells its product in more than 60 countries across the world. The products are manufactured in a state of the art manufacturing facility located in Surat. The Company is ISO 9001 and ISO 13485 certified & it has also obtained CE certification for all of its products.
For more information visit: www.smtpl.com
Samara is an India-focused private equity fund managing nearly $600 million across multiple funds and co-investments. It focuses on partnering with exceptional management teams, in both minority as well as buyout situations. While being sector agnostic, Samara prefers investments in healthcare, consumer and financial services space. Healthcare investments of Samara include minority investments in Thyrocare Laboratories and Asian Institute of Gastroenterology and buyout of Lotus Surgicals and Adcock Ingram’s India portfolio. Amongst the non-healthcare sectors, it has investments in companies like Flemingo Duty Free, RBL Bank, Sapphire Foods, Paradise Food Court, Iron Mountain (India).
Source: Sahajanand Medical Technologies